Phaseline

Companies › Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company): clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MORF-057
Selective integrin α4β7 inhibitor
ITGA4, ITGB7Phase 2Inflammatory Bowel DiseasesSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05611671MORF-057Phase 2Inflammatory Bowel DiseasesImmunologyNov 2024
NCT06226883MORF-057Phase 2Inflammatory Bowel DiseasesImmunologySep 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

ITGA4 (1) ITGB7 (1)

Companies with the same targets

Takeda Roche 7 Hills Pharma Gilead Sciences

Companies built like this

Calixis Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing) Agomab Spain S.L.U.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.